AstraZeneca

Open: 67.74 Close: 67.1 Change: -0.64

Stop reading the whole internet to decide if you want to invest in AstraZeneca.

Are looking for the most relevant information about AstraZeneca? Investor spend a lot of time searching for information to make investment decisions in AstraZeneca. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, high, Astrazeneca, PLC, company, AZN, Astra, and the most common words in the summary are: astrazeneca, bloomberg, company, market, subscribe, see, news, . One of the sentences in the summary was: Astrazenec is carrying a Zacks Rank of #3 (Hold) AstraZeneca is currently being traded …

Concept Map

Semantic Network

Stock Summary

AstraZeneca PLC focuses on the discovery, development, manufacture, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa,.

Today's Summary

Astrazeneca plc (AZN) up 0.98% in premarket trading. Astrazenec is carrying a Zacks Rank of #3 (Hold) AstraZeneca is currently being traded at a Forward P/E ratio.

Today's News

Astrazeneca PLC U.K.: London Add to Watchlist 0.00 AZN Real Time Quote About AstraZeneca Plc. Company engages in the research, development, manufacture, and commercialization of prescription medicines. AstraZeneca plc (AZN) up 0.98% in premarket trading. Astra has the 84th highest Short-Term Technical score in the Drug Manufacturers - General industry. AstraZeneca has made 36 investments. The company recently partnered with Allorion Therapeutics on January 1, 2024. Astra has 10 strategic partners and customers. Astrazeneca has reported positive data from the EMERALD-1 Phase III trial of its human monoclonal antibody Imfinzi (durvalumab) plus TACE and bevacizumab. Trial of AstraZenecas regimen was carried out across 157 centres in 18 countries. AstraZeneca PLC closed £18.46 short of its 52-week high (£123.92) The company reached that high on April 18. Astrazeneca PLC ADR closed $9.46 below its 52-week high ($76.56), which the company achieved on April 25th. Astrazenec is carrying a Zacks Rank of #3 (Hold) Currently, AstraZeneca is currently being traded at a Forward P/E ratio of 15.95. AstraZeneca agreed to acquire Chinese cell therapy developer Gracell Biotechnologies Inc. Dec 21: FDA signed off on first and only self-administered treatment for polyneuropathy in hereditary transthyretin-mediated amyloidosis.

Stock Profile

"AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom."

Keywords

The game is changing. There is a new strategy to evaluate AstraZeneca fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, high, Astrazeneca, PLC, company, AZN, Astra, and the most common words in the summary are: astrazeneca, bloomberg, company, market, subscribe, see, news, . One of the sentences in the summary was: Astrazenec is carrying a Zacks Rank of #3 (Hold) AstraZeneca is currently being traded at a Forward P/E ratio.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #astrazeneca #bloomberg #company #market #subscribe #see #news.